Shimla Online

Rich Insights into the Gallbladder Cancer Pipeline and Clinical Trial Analysis Featuring 10+ Companies and Therapies

 Breaking News
  • No posts were found

Rich Insights into the Gallbladder Cancer Pipeline and Clinical Trial Analysis Featuring 10+ Companies and Therapies

March 07
17:32 2023
Rich Insights into the Gallbladder Cancer Pipeline and Clinical Trial Analysis Featuring 10+ Companies and Therapies

DelveInsight’s, “Gallbladder cancer Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Gallbladder cancer pipeline landscape. It covers the Gallbladder cancer pipeline drug profiles, including Gallbladder cancer clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

For Gallbladder Cancer Emerging drugs, the Gallbladder Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Gallbladder Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Gallbladder Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Gallbladder Cancer clinical trials studies, Gallbladder Cancer NDA approvals (if any), and product development activities comprising the technology, Gallbladder Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Gallbladder Cancer Pipeline Report

 

  • DelveInsight’s Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.

 

  • The leading Gallbladder Cancer Companies includes Celgene, MedImmune, Ohara Pharmaceuticals, and others.

 

  • Promising Gallbladder Cancer Pipeline Therapies includes M7824, Panitumumab, oxaliplatin, exatecan mesylate, ZD6474, Vandetanib, Gemcitabine, Capecitabine, Cisplatin, gemcitabine hydrochloride, and others.

 

  • The Gallbladder Cancer companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The Gallbladder Cancer pipeline therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.

 

Request a sample and discover the recent breakthroughs happening in the Gallbladder Cancer Pipeline landscape @ Gallbladder Cancer Pipeline Outlook Report

 

Gallbladder Cancer Overview

Gallbladder cancer is a small, pear shaped organ located beneath the liver. The bladder stores bile enzymes produced by the liver and helps in digestion. Gallbladder cancer is a rare type of cancer that is characterized by the abnormal growth of cells in the Gallbladder cancer area. Most of the Gallbladder cancer begins in glandular cells which form the lining of the inner surface of the organ. This type of cancer is very rare and is caused due to the DNA mutations in the Gallbladder cancer cells. Gallbladder cancer is more common in middle aged women with a history of gallstones. However, it can also occur in men. Gallbladder cancer can be of various types such as papillary adenocarcinomas, adenosquamous carcinoma, squamous cell carcinoma, and others.

 

Gallbladder Cancer Emerging Drugs Profile

 

  • Durvalumab: Celgne

Celgene’ new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.

 

  • ONC 201: Ohara Pharmaceuticals

Ohara Pharmaceutical’s “breakthrough” drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.

 

For further information, refer to the detailed Gallbladder Cancer Drugs Launch, Gallbladder Cancer Developmental Activities, and Gallbladder Cancer News, click here for Gallbladder Cancer Ongoing Clinical Trial Analysis

 

Gallbladder Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Gallbladder cancer. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.

 

Gallbladder Cancer Pipeline Segmentation: Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Find out more about the Gallbladder Cancer Pipeline Segmentation, Therapeutics Assessment, and Gallbladder Cancer Emerging Drugs @ Gallbladder Cancer Treatment Landscape

 

Scope of the Gallbladder Cancer Pipeline Report

 

  • Coverage- Global

 

  • Gallbladder Cancer Companies- Celgene, MedImmune, Ohara Pharmaceuticals, and others.

 

  • Gallbladder Cancer Pipeline Therapies- M7824, Panitumumab, oxaliplatin, exatecan mesylate, ZD6474, Vandetanib, Gemcitabine, Capecitabine, Cisplatin, gemcitabine hydrochloride, and others.

 

  • Gallbladder Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Gallbladder Cancer Pipeline Companies and Therapies, click here @ Gallbladder Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gallbladder cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Gallbladder cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Gallbladder cancer Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. Durvalumab : Celgene
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. ONC 201: Ohara Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Gallbladder cancer Key Companies
  17. Gallbladder cancer Key Products
  18. Gallbladder cancer- Unmet Needs
  19. Gallbladder cancer- Market Drivers and Barriers
  20. Gallbladder cancer- Future Perspectives and Conclusion
  21. Gallbladder cancer Analyst Views
  22. Gallbladder cancer Key Companies
  23. Appendix

 

Got Queries? Find out the related information on Gallbladder Cancer Mergers and acquisitions, Gallbladder Cancer Licensing Activities @ Gallbladder Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/